Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
NCT ID: NCT06269302
Last Updated: 2024-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
346 participants
OBSERVATIONAL
2022-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis
NCT02240953
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
NCT03292666
The Study of Warfarin Maintenance Dose in Chinese Patients
NCT01855737
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
NCT02591732
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
NCT04394234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with recurrent gastrointestinal bleeding
The data of all patients who applied to Samsun Training and Research Hospital for 12 months in 2022 and diagnosis of upper gastrointestinal bleeding and hospitalized by Internal Medicine and Gastroenterology clinics or who underwent outpatient endoscopy were included in the study.Patients who had recurrent upper GI bleeding were detected by controlling them over the hospital software system and by reaching each patient again. The frequency of use of new generation oral anticoagulants in patients with rebleeding was determined, and data such as rebleeding rate, length of hospital stay, need for transfusion, and mortality were analyzed in the groups who did not use this drug and those who used it.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Upper gastrointestinal bleeding
* 12 months follow-up
Exclusion Criteria
* Lower gastrointestinal bleeding
* Esophageal variceal bleeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsun Education and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Duriye Sila Karagoz Ozen
MD, Internal Medicine Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
DÜRİYE SILA KARAGÖZ ÖZEN, MD
Role: PRINCIPAL_INVESTIGATOR
Samsun Education and Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsun Education and Research Hospital
Samsun, İlkadım, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.